Publication Name	World Journal of Gastroenterology
Manuscript ID	62252
Country	Poland

Received	2021-01-11 18:32
Peer-Review Started	2021-01-11 18:33
To Make the First Decision
Return for Revision	2021-01-23 03:21
Revised	2021-01-24 20:40
Second Decision	2021-02-23 01:22
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2021-03-01 04:24
Articles in Press	2021-03-01 04:24
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-03-08 04:38
Publish the Manuscript Online	2021-03-17 06:19

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Review
Article Title	Genotype 3-hepatitis C virus’ last line of defense
Manuscript Source	Invited Manuscript
All Author List	Dorota Zarębska-Michaluk
ORCID	Author(s) ORCID Number Dorota Zarębska-Michaluk http://orcid.org/0000-0003-0938-1084
Funding Agency and Grant Number
Corresponding Author	Dorota Zarębska-Michaluk, N/A, Professor, Department of Infectious Diseases, Jan Kochanowski University, Żeromskiego 5, Kielce 25-369, Świętokrzyskie, Poland. dorota1010@tlen.pl
Key Words	Hepatitis C virus; Genotype 3; Antiviral treatment; Interferon; Direct-acting antivirals; Pangenotypic
Core Tip	Genotype 3 which is second in frequency worldwide, is unique among genotypes of hepatitis C virus in its higher rate of steatosis, accelerated fibrosis progression, and lower cure rates. This paper describes the genotype-specific mechanisms of liver injury and provides an overview of therapeutic options. Currently, available highly potent pangenotypic regimens have revolutionized the treatment of genotype 3 infection, however, patients with liver cirrhosis and those who fail to response to direct-acting antiviral therapy still present a therapeutic challenge.
Publish Date	2021-03-17 06:19
Citation	Zarębska-Michaluk D. Genotype 3-hepatitis C virus’ last line of defense. World J Gastroenterol 2021; 27(11): 1006-1021
URL	https://www.wjgnet.com/1007-9327/full/v27/i11/1006.htm
DOI	https://dx.doi.org/10.3748/wjg.v27.i11.1006

Full Article (PDF)	WJG-27-1006.pdf
Full Article (Word)	WJG-27-1006.docx
Manuscript File	62252_Auto_Edited_LM.docx
Answering Reviewers	62252-Answering reviewers.pdf
Audio Core Tip	62252-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	62252-Conflict-of-interest statement.pdf
Copyright License Agreement	62252-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	62252-Language certificate.pdf
Peer-review Report	62252-Peer-review(s).pdf
Scientific Misconduct Check	62252-Scientific misconduct check.pdf
Scientific Editor Work List	62252-Scientific editor work list.pdf
CrossCheck Report	62252-CrossCheck report.pdf